11.17.08
Dermazone Solutions has been given the green light by the Florida Department of Health to produce prescription drugs at its St. Petersburg, FL facility. Already active in over-the-counter (OTC) pharmaceuticals and cosmeceutical contract manufacturing, Dermazone can now provide formulating, manufacturing and packaging services for prescription drugs.
Dermazone met the Florida statute requirements and pedigree law requirements by instituting comprehensive standard operating procedures (SOPs) and ensuring the facility is, at all times, working in compliance with the statute, which was designed to “safeguard the public health and promote the public welfare by protecting the public from injury by product use and merchandising deceit involving drugs, devices and cosmetics.” Dermazone developed these SOPs to cover a spectrum of requirements including meeting laboratory standards, transit and storage requirements, authentication requirements, labeling and advertising compliance requirements and pedigree process requirements, according to the company.
Dermazone anticipates that in the next two years, prescription manufacturing will account for approximately 60% of its manufacturing revenues. More info: www.dermazone.com
Dermazone met the Florida statute requirements and pedigree law requirements by instituting comprehensive standard operating procedures (SOPs) and ensuring the facility is, at all times, working in compliance with the statute, which was designed to “safeguard the public health and promote the public welfare by protecting the public from injury by product use and merchandising deceit involving drugs, devices and cosmetics.” Dermazone developed these SOPs to cover a spectrum of requirements including meeting laboratory standards, transit and storage requirements, authentication requirements, labeling and advertising compliance requirements and pedigree process requirements, according to the company.
Dermazone anticipates that in the next two years, prescription manufacturing will account for approximately 60% of its manufacturing revenues. More info: www.dermazone.com